Answers are grounded in this paper and cite their sources.
Bioactive peptides and peptide-based therapeutics have emerged as a rapidly expanding class of pharmacological agents used to treat metabolic diseases, cancer, infectious diseases, and cardiovascular disorders. Advances in peptide engineering, structural optimization, and delivery technologies have accelerated the clinical translation of peptide drugs. Concurrently, pharmacogenomics and toxicogenomics are transforming precision medicine by enabling individualized prediction of drug efficacy, adverse reactions, and toxicological responses. Pharmacogenomics examines how genetic variability influences pharmacokinetics and pharmacodynamics, whereas toxicogenomics integrates transcriptomics, proteomics, metabolomics, and systems biology to characterize molecular toxicity pathways. This study comprehensively reviews the intersection of pharmacogenomics and toxicogenomics in bioactive peptides, with emphasis on therapeutic peptides and peptide drugs. We also discuss genomic determinants of peptide drug response, toxicogenomic biomarkers, omics-based safety evaluation, regulatory perspectives, computational approaches, and future directions for precision peptide therapeutics.
No takes yet. Share an insight, caveat, or question.
Ghorani‐Azam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: